MDM2 SNP309 and cancer risk: a combined analysis.
暂无分享,去创建一个
[1] K. Hemminki,et al. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin , 2007, The British journal of dermatology.
[2] J. Klijn,et al. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling , 2007, Breast Cancer Research and Treatment.
[3] H. Iwata,et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients , 2007, Breast Cancer Research.
[4] F. He,et al. MDM2 Promoter SNP309 Is Associated with Risk of Occurrence and Advanced Lymph Node Metastasis of Nasopharyngeal Carcinoma in Chinese Population , 2007, Clinical Cancer Research.
[5] Gustavo Stolovitzky,et al. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. , 2007, Cancer research.
[6] Carl W. Miller,et al. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. , 2007, Gynecologic oncology.
[7] A. Levine,et al. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans , 2007, Oncogene.
[8] Dong Sun Kim,et al. Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer , 2007, Molecular carcinogenesis.
[9] R. Scott,et al. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients , 2007, International journal of cancer.
[10] David J. Hunter,et al. The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies , 2006, Cancer Causes & Control.
[11] Rochelle L. Garcia,et al. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. , 2006, Gynecologic oncology.
[12] I. Yulug,et al. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. , 2006, Anticancer research.
[13] M. Spitz,et al. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. , 2006, Carcinogenesis.
[14] J. Park,et al. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. , 2006, Lung cancer.
[15] Y. Hirooka,et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Neuberg,et al. Matrix Metalloproteinase Polymorphisms and Survival in Stage I Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.
[17] T. Ozcelik,et al. MDM2 T309G polymorphism is associated with bladder cancer. , 2006, Anticancer research.
[18] D. Eccles,et al. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. , 2006, Cancer letters.
[19] Hongbing Shen,et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. , 2006, Cancer letters.
[20] N. Kato,et al. MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 2006, Clinical Cancer Research.
[21] E. Bowman,et al. MDM2 SNP309 and SNP354 Are Not Associated with Lung Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.
[22] S. Zienolddiny,et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer , 2006, International journal of cancer.
[23] Hiroyuki Yamamoto,et al. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells , 2006, Journal of Medical Genetics.
[24] A. Levine,et al. MDM2 SNP309 accelerates colorectal tumour formation in women , 2006, Journal of Medical Genetics.
[25] Julie E Goodman,et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.
[26] A. Levine,et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.
[27] D. Eccles,et al. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers , 2006, BMC Cancer.
[28] Hongbing Shen,et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population , 2006, International journal of cancer.
[29] R. Bertorelle,et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. , 2006, Journal of the National Cancer Institute.
[30] P. Bugert,et al. The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer. , 2006, Cancer research.
[31] R. Millikan,et al. No Association Between the MDM2 −309 T/G Promoter Polymorphism and Breast Cancer in African-Americans or Whites , 2006, Cancer Epidemiology Biomarkers & Prevention.
[32] Wen Tan,et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer , 2006, Human mutation.
[33] A. Levine,et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[34] G. Tomlinson,et al. MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia , 2005, Leukemia.
[35] C. Bonaïti‐pellié,et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.
[36] W. Tan,et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. , 2005, Cancer research.
[37] Sandya Liyanarachchi,et al. p53 Codon 72 and MDM2 SNP309 Polymorphisms and Age of Colorectal Cancer Onset in Lynch Syndrome , 2005, Clinical Cancer Research.
[38] L. Aaltonen,et al. The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck , 2005, Journal of Medical Genetics.
[39] A. Levine,et al. A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells* , 2005, Journal of Biological Chemistry.
[40] A. Levine,et al. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. , 2005, Cancer research.
[41] Ruiwen Zhang,et al. p53-independent activities of MDM2 and their relevance to cancer therapy. , 2005, Current cancer drug targets.
[42] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[43] D. Easton,et al. EMGM Abstracts , 2003, Genetic epidemiology.
[44] J. Peto,et al. The future of association studies of common cancers , 2003, Human Genetics.
[45] M. Oren,et al. The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.
[46] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[47] F. McCormick,et al. Opposing Effects of Ras on p53 Transcriptional Activation of mdm2 and Induction of p19ARF , 2000, Cell.
[48] M. Oren,et al. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. , 1995, Nucleic acids research.
[49] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[50] Haoyang,et al. MDM 2 Promoter SNP 309 Is Associated with Risk of Occurrence and Advanced Lymph NodeMetastasis of Nasopharyngeal Carcinoma in Chinese Population , 2007 .
[51] L. J. Veer,et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes , 2007, European Journal of Human Genetics.
[52] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM 2 Gene Disrupts the Oscillation of p 53 and MDM 2 Levels in Cells , 2007 .
[53] P. Bugert,et al. The Single Nucleotide Polymorphism IVS 1 + 309 in Mouse Double Minute 2 Does Not Affect Risk of Familial Breast Cancer , 2006 .
[54] N. Kato,et al. MDM 2 Promoter SNP 309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 2006 .
[55] L. Aaltonen,et al. The MDM 2 promoter polymorphism SNP 309 T R G and the risk of uterine leiomyosarcoma , colorectal cancer , and squamous cell carcinoma of the head and neck , 2005 .
[56] W. Tan,et al. The Role of P 53 and MDM 2 Polymorphisms in the Risk of Esophageal Squamous Cell Carcinoma , 2005 .